



SCN8A-DEE = SCN8A Developmental and Epileptic Encephalopathy Syndrome. Neurocrine Biosciences has global rights, unless otherwise noted. Neurocrine Biosciences shares profits and losses on NBI-1065845 with Takeda Pharmaceutical Company Limited.

\* Mitsubishi Tanabe Pharma Corporation has commercialization rights in Japan and other select Asian markets.  
## Licensed from Xenon Pharmaceuticals, Inc.

¶ Licensed from Takeda Pharmaceutical Company Limited.  
†† Licensed from Nxera Pharma (formerly Sosei Heptares).

\*\* Nxera Pharma (formerly Sosei Heptares) has retained rights in Japan; Neurocrine Biosciences may opt-in to a 50:50 cost and revenue share upon certain development events.